T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Garfall, Alfred L., Dancy, Ehren K., Cohen, Adam D., Hwang, Wei-Ting, Fraietta, Joseph A., Davis, Megan M., Levine, Bruce L., Siegel, Don L., Stadtmauer, Edward A., Vogl, Dan T., Waxman, Adam, Rapoport, Aaron P., Milone, Michael C., June, Carl H., Melenhorst, J. Joseph
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2019
Subjects:
Stimulus Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784521/
https://ncbi.nlm.nih.gov/pubmed/31575532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000600
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items